Information on new approvals and medication safety that rheumatologists need to know
Search results for: biosimilars
When Will Generic Biologic Drugs Become Commercially Available?
Biosimilars are challenging to produce, but progress is being made
ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
The Biologics Price Competition and Innovation Act of 2009 would spur the development of products intended to be biosimilar to approved therapies
South Korea Okays First Officially Approved Monoclonal Antibody for RA
11 Products Looking for U.S. Marketing Nod
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
Drug UPDATES
Information on New Approvals and Medication Safety
Build a Solid Foundation for Patient Care: 2011 Professional Meetings
You’ve come to rely on the ACR for meeting your professional development needs. Along with the ACR/ARHP Annual Scientific Meeting, the College provides symposia and other courses designed especially for rheumatology health professionals.
Drug Updates
Information on New Approvals and Medication Safety
The Good and Bad of Healthcare Reform
Even though the law was passed, the work of reform is just beginning
Drug Safety
What can the ACR do?
- « Previous Page
- 1
- …
- 29
- 30
- 31